Robert Smale

IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

Endosialin-Expressing Pericytes Promote Metastatic Dissemination

Triple-negative breast cancer molecular subtyping and treatment progress

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level

A view on drug resistance in cancer

CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity

Strategies and challenges for the next generation of antibody–drug conjugates

A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application

Development of therapeutic antibodies for the treatment of diseases

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression

Epithelial Mesenchymal Transition in Tumor Metastasis

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

Flavylium Polymethine Fluorophores for Near‐ and Shortwave Infrared Imaging

Flavylium Polymethine Fluorophores for Near‐ and Shortwave Infrared Imaging

Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies

Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma

Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease

Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance